Polaris Partners

Activity in this selectiontriple-point-capital-12934464

By stage

Series B3

Series A1

Undisclosed1

Biotech4

Healthtech1

United States5

5 in this selection

Aug 30

Structured data and AI agents for clinical development and pharmaceutical trial operations.

$37.3MSeries B

Participant

Jun 2

Develops novel therapeutics for glaucoma and retinal diseases

$17MSeries A

Role not disclosed

Mar 18

Develops a novel class of potent and precise antibody therapies to treat a broad range of cancers

$77MSeries B

Role not disclosed

Jan 27

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosed

Role not disclosed

Jan 8

Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...

$107MSeries B

Role not disclosed